NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $5.57 +0.13 (+2.41%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tango Therapeutics Stock (NASDAQ:TNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tango Therapeutics alerts:Sign Up Key Stats Today's Range$5.45▼$5.9150-Day Range$1.10▼$5.4452-Week Range$1.03▼$12.02Volume211,724 shsAverage Volume1.57 million shsMarket Capitalization$603.84 millionP/E RatioN/ADividend YieldN/APrice Target$12.20Consensus RatingBuy Company Overview Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. Read More Tango Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreTNGX MarketRank™: Tango Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 651st out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTango Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tango Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.60% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Tango Therapeutics has recently decreased by 1.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted26.60% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Tango Therapeutics has recently decreased by 1.76%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment0.44 News SentimentTango Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Tango Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows4 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Stock News HeadlinesTango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.20 Consensus Target Price from AnalystsJuly 1 at 2:51 AM | americanbankingnews.comTango Therapeutics doses first patient in cancer drug combo trialJune 29 at 10:06 AM | uk.investing.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 2 at 2:00 AM | Paradigm Press (Ad)Tango Therapeutics (NASDAQ:TNGX) Trading 6.5% Higher - Here's What HappenedJune 29 at 4:11 AM | americanbankingnews.comTango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer TrialJune 27, 2025 | marketwatch.comTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerJune 27, 2025 | globenewswire.comTango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - NasdaqJune 25, 2025 | nasdaq.comTango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trialsJune 16, 2025 | investing.comSee More Headlines TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $3.09 at the start of the year. Since then, TNGX stock has increased by 76.1% and is now trading at $5.44. View the best growth stocks for 2025 here. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.02. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative net margin of 322.67% and a negative trailing twelve-month return on equity of 62.75%. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tango Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/12/2025Today7/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNGX CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$12.20 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+117.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.30 million Net Margins-322.67% Pretax Margin-322.17% Return on Equity-62.75% Return on Assets-39.94% Debt Debt-to-Equity RatioN/A Current Ratio6.26 Quick Ratio6.26 Sales & Book Value Annual Sales$42.07 million Price / Sales14.47 Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book3.02Miscellaneous Outstanding Shares108,390,000Free Float100,264,000Market Cap$608.61 million OptionableOptionable Beta1.61 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:TNGX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.